Company news
Aytu BioPharma, Inc. news in 2025
Aytu BioPharma, Inc.'s news releases, calls and decks from 2025, newest first.
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
December 18, 2025
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
December 15, 2025
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
November 24, 2025
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
November 13, 2025
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
November 5, 2025
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
October 28, 2025
Aytu BioPharma to Present at Upcoming October 2025 Conferences
October 10, 2025
Aytu BioPharma to Present at Upcoming September 2025 Conferences
September 24, 2025
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
September 23, 2025
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
September 16, 2025
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
June 25, 2025
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
June 22, 2025
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
June 9, 2025
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
June 6, 2025
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
June 6, 2025
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
May 14, 2025
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
May 7, 2025
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 21, 2025
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
February 11, 2025
Calls in 2025
Decks in 2025
- Investor Presentation (June 2025)
Investor deck · 33 slides · Jun 17, 2025